Let's consider two stocks trading well below $200 that have what it takes to do that: Novo Nordisk (NYSE: NVO) and DexCom ...

The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below ... acquire facilities in the ...

More than 62,000 seniors in Western New York will benefit from three measures discussed during a visit to Buffalo on Monday by U.S. Senate Majority Leader Chuck Schumer.

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) A/S fell on Wednesday after Bloomberg reported that Ozempic, Novo ...

SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to ...

This executive change arrives at a critical juncture for Eli Lilly, as the company invests billions to expand manufacturing capacity and meet soaring demand for its diabetes and weight loss drugs ...

The FDA has granted approval to 29 novel drugs this year. Innovation in the industry is at its peak, with spaces like weight ...

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...

The chart setup is quite strong, but its valuation is high considering its EPS growth projection. Moreover, secular headwinds could be in play if GLP-1 weight loss and diabetes drugs prove to help ...

PLATTSBURGH — A new federal program that is lowering prescription drug costs will aid seniors who are trying to make ends ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...

These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the last two quarters.